Pirfenidone is the only medicine approved for IPF anywhere in the world.

Pirfenidone is marketed by InterMune in the EU as Esbriet® and is currently in a Phase 3 clinical trial in the United States. Pirfenidone is also approved for the treatment of IPF in Japan, where it is marketed by Shionogi & Co. Ltd. under the trade name Pirespa®.

View Pipeline

ACTIMMUNE (Interferon gamma-1b)

For additional information on Actimmune® including full
prescribing information, please go to www.actimmune.com.

More about Actimmune®

Ascend Clinical Trial

For information on the ASCEND Phase 3 study of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) please visit clinicaltrials.gov.

Events

April 26, 2012

InterMune to conduct conference call and webcast on Thursday, April 26, 2012 at 4:30PM EDT

View Our Event Calendar

News

April 26, 2012

InterMune Reports First Quarter 2012 Financial Results And Business Highlights

April 19, 2012

InterMune To Release First Quarter Financial Results On April 26

View All Press Releases